BioLineRx, a clinical-stage biopharmaceutical company, will release its Q1 2026 financial results on May 27, 2026. Analysts expect an earnings loss of $1.04 per share and revenue of $343,000, reflecting ongoing development costs typical for its growth phase. Despite the loss and a negative P/E ratio, the company shows solid financial health with a current ratio of 1.95 and a manageable debt-to-equity ratio of 0.56. Investors will also hear from CEO Philip Serlin in a conference call following the report, providing insights into the company’s progress in oncology and rare disease treatments.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Hi-View Resources Inc. has started its 2026 exploration program in the Toodoggone Mining District, British Columbia, focusing on porphyry targets at key sites like Lawyer’s East, Borealis, and Golden Stranger. The program includes 50 line kilometres ...
The U.S. Patent and Trademark Office (USPTO) has introduced an AI-assisted image search feature in its public trademark search system, TM Search, using technology from Clarivate Plc. This new tool allows users to upload images and compare them agains...
AIB Data Centers Inc. is considered a speculative buy with a $3.50 price target based on its 65 MW energized capacity. The investment case depends heavily on securing a single anchor lease at its CLT-01 facility, which would validate its business mod...
Experian PLC started its 2027 financial year with a 10% revenue increase in the first quarter, driven by strong demand in North America and Latin America. Organic growth was 7%, with North America growing 7% despite a 2% drop in consumer services due...
